ZA200004362B - Use of CRF antagonists and related compositions. - Google Patents

Use of CRF antagonists and related compositions.

Info

Publication number
ZA200004362B
ZA200004362B ZA200004362A ZA200004362A ZA200004362B ZA 200004362 B ZA200004362 B ZA 200004362B ZA 200004362 A ZA200004362 A ZA 200004362A ZA 200004362 A ZA200004362 A ZA 200004362A ZA 200004362 B ZA200004362 B ZA 200004362B
Authority
ZA
South Africa
Prior art keywords
related compositions
crf antagonists
crf
antagonists
compositions
Prior art date
Application number
ZA200004362A
Other languages
English (en)
Inventor
Yuhpyng Liang Chen
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of ZA200004362B publication Critical patent/ZA200004362B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • A61P5/12—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH for decreasing, blocking or antagonising the activity of the posterior pituitary hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Otolaryngology (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Hydrogenated Pyridines (AREA)
  • Quinoline Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
ZA200004362A 1999-08-27 2000-08-24 Use of CRF antagonists and related compositions. ZA200004362B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US15118399P 1999-08-27 1999-08-27

Publications (1)

Publication Number Publication Date
ZA200004362B true ZA200004362B (en) 2002-02-25

Family

ID=22537665

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200004362A ZA200004362B (en) 1999-08-27 2000-08-24 Use of CRF antagonists and related compositions.

Country Status (12)

Country Link
US (3) US6432989B1 (hu)
EP (1) EP1082960A3 (hu)
JP (1) JP2001097889A (hu)
KR (1) KR20010050223A (hu)
AU (1) AU776077B2 (hu)
CA (1) CA2316662A1 (hu)
CO (1) CO5190684A1 (hu)
HU (1) HUP0003386A3 (hu)
IL (1) IL137935A0 (hu)
NZ (1) NZ506562A (hu)
PE (1) PE20010528A1 (hu)
ZA (1) ZA200004362B (hu)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6432989B1 (en) * 1999-08-27 2002-08-13 Pfizer Inc Use of CRF antagonists to treat circadian rhythm disorders
WO2001024807A2 (en) 1999-10-01 2001-04-12 Johnson & Johnson Consumer Companies, Inc. Method for calming human beings using personal care compositions
EP1149583A3 (en) * 2000-04-13 2001-11-14 Pfizer Products Inc. Combinations of corticotropin releasing factor antagonists and growth hormone secretagogues
BR0209267A (pt) * 2001-04-30 2004-06-15 Glaxo Group Ltd Pirimidinas fundidas como antagonistas do fator de liberação de corticotropina (crf)
US8101209B2 (en) 2001-10-09 2012-01-24 Flamel Technologies Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles
US6602911B2 (en) * 2001-11-05 2003-08-05 Cypress Bioscience, Inc. Methods of treating fibromyalgia
GB2411478A (en) 2002-01-29 2005-08-31 Johnson & Johnson Consumer Method of measuring the stress or relaxation level of a mammal
GB0203045D0 (en) * 2002-02-08 2002-03-27 Johnson & Johnson Consumer Method of afefecting sleep and sleep-related behaviours
JP2005531599A (ja) 2002-05-29 2005-10-20 スリーエム イノベイティブ プロパティズ カンパニー イミダゾ［４，５−ｃ］ピリジン−４−アミンのための方法
AU2003229408A1 (en) 2002-06-10 2003-12-22 Philippe Kriwin Oral antidepressant formulation comprising a selective serotonin_reuptake inhibitor
US20100189797A1 (en) 2002-06-10 2010-07-29 Julien Mendlewicz Oral antidepressant formulation
EP1622910A1 (en) * 2003-05-05 2006-02-08 F. Hoffmann-La Roche Ag Fused pyrimidine derivatives with crf activity
WO2005018551A2 (en) 2003-08-12 2005-03-03 3M Innovative Properties Company Oxime substituted imidazo-containing compounds
WO2005014557A1 (en) 2003-08-12 2005-02-17 F.Hoffmann-La Roche Ag Tetrahydroquinazoline derivatives as cfr antagonists
CN1835753A (zh) 2003-08-12 2006-09-20 弗·哈夫曼-拉罗切有限公司 作为促皮质释放素(cfr)拮抗剂的螺－取代的四氢喹唑啉
WO2005020999A1 (en) 2003-08-27 2005-03-10 3M Innovative Properties Company Aryloxy and arylalkyleneoxy substituted imidazoquinolines
JP2007504269A (ja) 2003-09-05 2007-03-01 スリーエム イノベイティブ プロパティズ カンパニー Ｃｄ５＋ｂ細胞リンパ腫の治療方法
US20050059744A1 (en) * 2003-09-12 2005-03-17 Allergan, Inc. Methods and compositions for the treatment of pain and other alpha 2 adrenergic-mediated conditions
MXPA06003705A (es) 2003-10-03 2006-06-20 3M Innovative Properties Co Imidazoquinolinas sustituidas con alcoxi.
US7544697B2 (en) 2003-10-03 2009-06-09 Coley Pharmaceutical Group, Inc. Pyrazolopyridines and analogs thereof
EP1677772B1 (en) * 2003-10-29 2009-08-26 Philippe Kriwin Oral antidepressant formulation comprising acetylsalicylic acid to accelerate onset of action
JP2007511535A (ja) 2003-11-14 2007-05-10 スリーエム イノベイティブ プロパティズ カンパニー ヒドロキシルアミン置換イミダゾ環化合物
CA2545774A1 (en) 2003-11-14 2005-06-02 3M Innovative Properties Company Oxime substituted imidazo ring compounds
ES2662903T3 (es) * 2003-11-25 2018-04-10 Smithkline Beecham (Cork) Limited Base libre de carvedilol, sales, formas anhidras o solvato de la misma, composiciones farmacéuticas correspondientes, formulaciones de liberación controlada, y procedimientos de tratamiento o administración
MXPA06005910A (es) 2003-11-25 2006-08-23 3M Innovative Properties Co Sistemas de anillo imidazo sustituido y metodos.
WO2005051325A2 (en) * 2003-11-25 2005-06-09 Sb Pharmco Puerto Rico Inc. Carvedilol compositions methods of treatment and delivery
JP4691506B2 (ja) * 2003-12-11 2011-06-01 アベンティス・ファーマスーティカルズ・インコーポレイテツド カゼインキナーゼＩεの阻害剤としての置換１Ｈ−ピロロ［３，２−ｂ，３，２−ｃ，及び２，３−ｃ］ピリジン−２−カルボキシアミド及び関連類似物
EP1697369A1 (en) * 2003-12-22 2006-09-06 SB Pharmco Puerto Rico Inc Crf receptor antagonists and methods relating thereto
EP1701955A1 (en) 2003-12-29 2006-09-20 3M Innovative Properties Company Arylalkenyl and arylalkynyl substituted imidazoquinolines
AU2004312508A1 (en) 2003-12-30 2005-07-21 3M Innovative Properties Company Imidazoquinolinyl, imidazopyridinyl, and imidazonaphthyridinyl sulfonamides
US20050171095A1 (en) * 2004-01-06 2005-08-04 Pfizer Inc Combination of CRF antagonists and 5-HT1B receptor antagonists
JP2008503444A (ja) * 2004-02-13 2008-02-07 エスビー・ファルムコ・プエルト・リコ・インコーポレイテッド Ｃｒｆ受容体アンタゴニスト、その調製法、その医薬組成物およびその使用
CA2556160A1 (en) * 2004-02-13 2005-09-01 Pfizer Products Inc. Therapeutic combinations of atypical antipsychotics with corticotropin releasing factor antagonists
US8697873B2 (en) 2004-03-24 2014-04-15 3M Innovative Properties Company Amide substituted imidazopyridines, imidazoquinolines, and imidazonaphthyridines
EP1750862B1 (en) 2004-06-04 2011-01-05 Teva Pharmaceutical Industries Ltd. Pharmaceutical composition containing irbesartan
WO2005123080A2 (en) 2004-06-15 2005-12-29 3M Innovative Properties Company Nitrogen-containing heterocyclyl substituted imidazoquinolines and imidazonaphthyridines
US8026366B2 (en) 2004-06-18 2011-09-27 3M Innovative Properties Company Aryloxy and arylalkyleneoxy substituted thiazoloquinolines and thiazolonaphthyridines
US7915281B2 (en) 2004-06-18 2011-03-29 3M Innovative Properties Company Isoxazole, dihydroisoxazole, and oxadiazole substituted imidazo ring compounds and method
EP1831221B1 (en) 2004-12-30 2012-08-08 3M Innovative Properties Company Substituted chiral fused 1,2 imidazo 4,5-c ring compounds
EP1831226B1 (en) 2004-12-30 2012-08-08 3M Innovative Properties Company Chiral tetracyclic compounds inducing interferon biosynthesis
JP2008530022A (ja) 2005-02-04 2008-08-07 コーリー ファーマシューティカル グループ，インコーポレイテッド 免疫反応調節物質を含む水性ゲル処方物
CA2597587A1 (en) 2005-02-11 2006-08-17 Coley Pharmaceutical Group, Inc. Oxime and hydroxylamine substituted imidazo[4,5-c] ring compounds and methods
EP1869043A2 (en) 2005-04-01 2007-12-26 Coley Pharmaceutical Group, Inc. Pyrazolopyridine-1,4-diamines and analogs thereof
AU2006232375A1 (en) 2005-04-01 2006-10-12 Coley Pharmaceutical Group, Inc. 1-substituted pyrazolo (3,4-c) ring compounds as modulators of cytokine biosynthesis for the treatment of viral infections and neoplastic diseases
CA2611256A1 (en) * 2005-06-10 2006-12-21 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Modulation of peripheral clocks in adipose tissue
US7994220B2 (en) * 2005-09-28 2011-08-09 Cypress Bioscience, Inc. Milnacipran for the long-term treatment of fibromyalgia syndrome
US7906506B2 (en) 2006-07-12 2011-03-15 3M Innovative Properties Company Substituted chiral fused [1,2] imidazo [4,5-c] ring compounds and methods
US8987232B2 (en) 2008-09-04 2015-03-24 The University Of Tokyo Agent for ameliorating brain hypofunction
EP2536720A1 (en) 2010-02-18 2012-12-26 Centro Nacional de Investigaciones Oncológicas (CNIO) Triazolo [4, 5 - b]pyridin derivatives
WO2014078568A1 (en) 2012-11-14 2014-05-22 The Johns Hopkins University Methods and compositions for treating schizophrenia
CN108025008A (zh) * 2015-06-22 2018-05-11 安比拉神经疗法公司 用于治疗物质使用障碍、成瘾和精神病的组合物和方法
WO2018002673A1 (en) 2016-07-01 2018-01-04 N4 Pharma Uk Limited Novel formulations of angiotensin ii receptor antagonists
CN110582278B (zh) 2017-03-10 2023-04-18 伊姆贝拉神经疗法公司 药物组合物及其用途
CN109528670B (zh) * 2018-12-28 2021-05-07 正大制药（青岛）有限公司 一种琥珀酸夫罗曲坦片及其制备方法

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4605642A (en) 1984-02-23 1986-08-12 The Salk Institute For Biological Studies CRF antagonists
US5063245A (en) 1990-03-28 1991-11-05 Nova Pharmaceutical Corporation Corticotropin-releasing factor antagonism compounds
FR2692893B1 (fr) 1992-06-24 1994-09-02 Sanofi Elf Dérivés alkylamino ramifiés du thiazole, leurs procédés de préparation et les compositions pharmaceutiques qui les contiennent.
PL176526B1 (pl) 1992-12-17 1999-06-30 Pfizer Pirolopirymidyny jako związki o działaniu antagonistów czynnika uwalniającego kortykotropinę
TW444018B (en) 1992-12-17 2001-07-01 Pfizer Pyrazolopyrimidines
WO1995010506A1 (en) 1993-10-12 1995-04-20 The Du Pont Merck Pharmaceutical Company 1n-alkyl-n-arylpyrimidinamines and derivatives thereof
US5968944A (en) 1994-06-06 1999-10-19 Pfizer Inc. Substituted pyrazoles as corticotropin-releasing factor (CRF) antagonists
TW530047B (en) 1994-06-08 2003-05-01 Pfizer Corticotropin releasing factor antagonists
US5646152A (en) * 1994-06-15 1997-07-08 Pfizer Inc. Methods of administering CRF antagonists
MX9606504A (es) 1994-06-16 1997-03-29 Pfizer Compuestos biciclicos.
US6020492A (en) 1995-05-12 2000-02-01 Neurogen Corporation Deazapurine derivatives; a new class of CRF1 specific ligands
US6403599B1 (en) 1995-11-08 2002-06-11 Pfizer Inc Corticotropin releasing factor antagonists
US5795905A (en) 1995-06-06 1998-08-18 Neurocrine Biosciences, Inc. CRF receptor antagonists and methods relating thereto
FR2735777B1 (fr) 1995-06-21 1997-09-12 Sanofi Sa Derives de 4-phenylaminothiazole, leur procede de preparation et les compositions pharmaceutiques les contenant
US5955613A (en) 1995-10-13 1999-09-21 Neurogen Corporation Certain pyrrolopyridine derivatives; novel CRF1 specific ligands
EP0863882B1 (en) 1995-10-17 2002-02-06 Janssen Pharmaceutica N.V. Amino substituted pyrimidines and triazines
DE69628804T2 (de) 1995-12-08 2003-12-18 Pfizer Inc., New York Substitutierte heterozyclische Derivate als CRF Antagonisten
CZ244598A3 (cs) 1996-02-07 1998-10-14 Janssen Pharmaceutica N.V. Pyrazolopyrimidiny jako antagonisty CRF receptoru
KR19990067390A (ko) 1996-02-07 1999-08-16 뉴로크린 바이오사이언시즈 인코퍼레이티드 티오페노피리미딘
WO1997035846A1 (en) 1996-03-26 1997-10-02 Dupont Pharmaceuticals Company Aryloxy- and arylthio-fused pyridines and pyrimidines and derivatives
US6326368B1 (en) 1996-03-27 2001-12-04 Dupont Pharmaceuticals Company Aryloxy- and arylthiosubstituted pyrimidines and triazines and derivatives thereof
ZA973884B (en) 1996-05-23 1998-11-06 Du Pont Merck Pharma Tetrahydropteridines and pyridylpiperazines for treatment of neurological disorders
EA006626B1 (ru) 1996-07-24 2006-02-24 Дюпон Фармасьютикалз Компани Азолопиримидины, фармацевтическая композиция и способ лечения
EA003188B1 (ru) 1996-08-06 2003-02-27 Пфайзер Инк Замещенные пиридо- или пиримидосодержащие 6,6- или 6,7-бициклические производные
US5861398A (en) 1996-08-26 1999-01-19 Alanex Corporation Benzoperimidine-carboxylic acids and derivatives thereof
TW477787B (en) 1996-08-27 2002-03-01 Pfizer Pyrido six-membered nitrogen-containing cyclic ring derivatives having corticotropin releasing factor antagonist activity and pharmaceutical composition containing same
CZ68199A3 (cs) 1996-08-28 1999-11-17 Pfizer Inc. 6,5-Heterobicyklické deriváty, farmaceutická kompozice na jejich bázi a způsob léčení chorob
DE69710594T2 (de) 1996-09-16 2002-08-29 Du Pont Pharmaceuticals Co., Wilmington Eine resorbierbare röntgenopake markierung enthaltendes chirurgisches implantat und verfahren zum verriegeln desselben in einem körper
FR2754258B1 (fr) 1996-10-08 1998-12-31 Sanofi Sa Derives d'aminothiazole, leur procede de preparation et les compositions pharmaceutiques les contenant
US5760225A (en) 1996-11-15 1998-06-02 Neurogen Corporation Certain pyrazole derivatives as corticotropin-releasing factor receptor CRF1 specific ligands
CA2275686C (en) 1996-12-18 2006-10-17 Neurogen Corporation Isoquinolinamine and phthalazinamine derivatives which interact with crf receptors
AU7890598A (en) 1996-12-27 1998-07-31 Yoshitomi Pharmaceutical Industries, Ltd. Fused pyrimidine compounds and medicinal use thereof
US5723608A (en) 1996-12-31 1998-03-03 Neurogen Corporation 3-aryl substituted pyrazolo 4,3-d!pyrimidine derivatives; corticotropin-releasing factor receptor (CRF1) specific ligands
CA2281525A1 (en) 1997-02-18 1998-08-20 Neurocrine Biosciences, Inc. Biazacyclic crf antagonists
ES2203937T3 (es) 1997-03-26 2004-04-16 Taisho Pharmaceutical Co., Ltd Derivados de 4-tetrahidropiridilpirimidina.
KR20000069312A (ko) 1997-04-22 2000-11-25 디르크 반테 Ｃｒｆ 길항성 티오페노피리딘
CA2272291C (en) 1997-04-22 2008-06-17 Janssen Pharmaceutica N.V. Crf antagonistic quino- and quinazolines
TW453999B (en) 1997-06-27 2001-09-11 Fujisawa Pharmaceutical Co Benzimidazole derivatives
PL337888A1 (en) 1997-07-03 2000-09-11 Du Pont Pharm Co Imidazoprimidines and imidazopyridines for use in treating neurological disorders
EP0994860A1 (en) 1997-07-03 2000-04-26 Du Pont Pharmaceuticals Company Aryl-and arylamino-substituted heterocycles as corticotropin releasing hormone antagonists
EP0937081A1 (en) 1997-08-22 1999-08-25 Du Pont Pharmaceuticals Company NITROGEN SUBSTITUTED IMIDAZO 4,5-c]PYRAZOLES AS CORTICOTROPIN RELEASING HORMONE ANTAGONISTS
NL1010018C2 (nl) 1997-09-09 1999-03-10 Duphar Int Res Chinoline en chinazoline derivaten met corticotropine releasing factor (CRF) antagonistische werking.
CN1542010A (zh) 1998-01-28 2004-11-03 �Ű�ҩƷ��˾ 吡咯并三嗪和嘧啶化合物
US6432989B1 (en) * 1999-08-27 2002-08-13 Pfizer Inc Use of CRF antagonists to treat circadian rhythm disorders

Also Published As

Publication number Publication date
IL137935A0 (en) 2001-10-31
NZ506562A (en) 2002-09-27
US20040082597A1 (en) 2004-04-29
CA2316662A1 (en) 2001-02-27
CO5190684A1 (es) 2002-08-29
AU776077B2 (en) 2004-08-26
HU0003386D0 (en) 2000-08-24
HUP0003386A3 (en) 2003-08-28
KR20010050223A (ko) 2001-06-15
US20020156089A1 (en) 2002-10-24
US6432989B1 (en) 2002-08-13
EP1082960A2 (en) 2001-03-14
HUP0003386A2 (hu) 2001-07-30
EP1082960A3 (en) 2002-03-20
JP2001097889A (ja) 2001-04-10
PE20010528A1 (es) 2001-05-10
AU5364400A (en) 2001-03-01

Similar Documents

Publication Publication Date Title
ZA200004362B (en) Use of CRF antagonists and related compositions.
ZA200006008B (en) Use of corticotropin releasing factor antagonists and related compositions.
HK1055897A1 (en) Antimicrobial compositions and methods of use
IL190220A0 (en) Novel composition and use
MXPA02004770A (es) Composiciones terapeuticas y metodos para su uso.
GB9903216D0 (en) Preservative compounds,compositions and methods of making and using the same
HK1048318B (zh) 取代的3-苯基-5-烷氧基-1，3，4-噁二唑-2-酮及其作為脂酶抑制劑的用途
EG22491A (en) Rest-breaking composition and use thereof
AU1152601A (en) Compositions and their use
AU5179800A (en) Mycolactone and related compounds, compositions and methods of use
GB9922135D0 (en) Compositions and uses
GB9927927D0 (en) Compound composition and use
HUP0201048A3 (en) Pseudomycin antifungal compositions and their use
HK1055288A1 (en) Novel aqueous composition and use of the same
GB9911606D0 (en) Composition and use
HUP0201308A2 (en) Imidazo-containing heterocyclic compounds, their compositions and uses
EG24062A (en) Novel composition and use
GB9918526D0 (en) Compositions of matter, use and products thereof
GB9912190D0 (en) Novel composition and use
GB9912189D0 (en) Novel composition and use
GB9927121D0 (en) Novel composition and use
GB9912191D0 (en) Novel composition and use
GB9912193D0 (en) Novel composition and use
GB9927119D0 (en) Novel composition and use
GB9927120D0 (en) Novel composition and use